# DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2

> **NCT03361098** · PHASE4 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 65 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Obesity

## Interventions

- **DRUG:** Dapagliflozin 10mg
- **DRUG:** Exenatide
- **OTHER:** placebo exenatide
- **OTHER:** placebo dapagliflozin

## Key facts

- **NCT ID:** NCT03361098
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-18
- **Primary completion:** 2019-11-25
- **Final completion:** 2020-03-25
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361098, "DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03361098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*